Quizartinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 359 publications

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.

Journal: Folia biologica
Published: April 14, 2026

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Journal: Haematologica
Published: April 01, 2026

Reply to: Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.

Reply to: Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026

Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.

Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026

Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to the TRAIL-Induced Apoptosis.

Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to the TRAIL-Induced Apoptosis.

Journal: Biochemistry. Biokhimiia
Published: February 17, 2026

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Journal: Journal of personalized medicine
Published: February 16, 2026

A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.

A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.

Journal: Cancers
Published: January 23, 2026

Management of Acute Myeloid Leukemia: A Review.

Management of Acute Myeloid Leukemia: A Review.

Journal: Cancers
Published: January 13, 2026

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms.

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms.

Journal: International journal of molecular sciences
Published: December 29, 2025

Cyclic IMS-MS Reveals Protonation-Site Preservation in Isobaric Fragments of Quizartinib Protomers via Charge-Remote Fragmentation.

Cyclic IMS-MS Reveals Protonation-Site Preservation in Isobaric Fragments of Quizartinib Protomers via Charge-Remote Fragmentation.

Journal: Journal of the American Society for Mass Spectrometry
Published: December 07, 2025

The Care and Cure of the Leukemias in 2026.

The Care and Cure of the Leukemias in 2026.

Journal: American journal of hematology
Published: December 03, 2025

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Showing 1-12 of 359

Last Updated: 04/28/2026